Moderna Therapeutics

Moderna looks for opportunities in China after registering legal entity
Moderna looks for opportunities in China after registering legal entity
Reuters
Moderna Therapeutics
China
Flag link:
Moderna vets help launch new RNA venture with $300M in largest financing round of 2023 so far
Moderna vets help launch new RNA venture with $300M in largest financing round of 2023 so far
Fierce Biotech
ReNAgade Therapeutics
RNA
Moderna Therapeutics
funding
Flag link:
Moderna, looking beyond vaccines, guides first mRNA protein replacement therapy past early clinical test
Moderna, looking beyond vaccines, guides first mRNA protein replacement therapy past early clinical test
Fierce Biotech
Moderna Therapeutics
MRNA
intracellular proteins
clinical trials
propionic acidemia
Flag link:
Here's How Moderna Turned a Profit in Q1 Despite Its Sales Declining by 69%
Here's How Moderna Turned a Profit in Q1 Despite Its Sales Declining by 69%
Motley Fool
Moderna Therapeutics
earnings
Flag link:
Moderna hits back at Alnylam's 'baseless' patent infringement claims
Moderna hits back at Alnylam's 'baseless' patent infringement claims
Fierce Pharma
Moderna Therapeutics
Alnylam
MRNA
vaccines
legals
Flag link:
A blockbuster year could be building
A blockbuster year could be building
EP Vantage
AbbVie
Amgen
AstraZeneca
Bristol Myers Squibb
Daiichi Sankyo
Eli Lilly
Gilead Sciences
Horizon Therapeutics
Merck
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
Flag link:
Revenues down for Moderna, up for Regeneron in Q1
Revenues down for Moderna, up for Regeneron in Q1
Medical Marketing and Media
Moderna Therapeutics
Regeneron
earnings
Flag link:
Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting
Moderna Announces Phase 1/2 Data on mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia (PA) to be Presented at the 2023 ASGCT Annual Meeting
BioSpace
Moderna Therapeutics
vaccines
mRNA-3927
propionic acidemia
Flag link:
The race for gold: Closing in on the first RSV vaccine
The race for gold: Closing in on the first RSV vaccine
Pharmaphorum
vaccines
RSV
GSK
Pfizer
Moderna Therapeutics
Flag link:
Second judge says US not liable in Moderna COVID-19 vaccine patent case
Second judge says US not liable in Moderna COVID-19 vaccine patent case
Reuters
Moderna Therapeutics
patents
intellectual property
legal
vaccines
COVID-19
Flag link:
Is Moderna Setting Expectations Too High?
Is Moderna Setting Expectations Too High?
Motley Fool
Moderna Therapeutics
vaccines
RSV
COVID-19
Flag link:
Finding the big spenders beyond big pharma
Finding the big spenders beyond big pharma
EP Vantage
R&D
Amgen
Bayer
Biogen
Gilead Sciences
Merck KGaA
Moderna Therapeutics
Novo Nordisk
Regeneron Pharmaceuticals
UCB
Vertex Pharmaceuticals
Flag link:
Moderna and Merck’s mRNA Cancer Vaccine Impresses but Experts Urge Caution
Moderna and Merck’s mRNA Cancer Vaccine Impresses but Experts Urge Caution
BioSpace
Moderna Therapeutics
Merck
MRNA
cancer vaccines
vaccines
Flag link:
Big pharma holds steady on research spending
Big pharma holds steady on research spending
EP Vantage
R&D
AbbVie
Amgen
AstraZeneca
Bayer
Biogen
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
GSK
JNJ
Merck
Merck KGaA
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
UCB
Vertex Pharmaceuticals
Flag link:
Moderna and IBM to Explore Quantum Computing and Generative AI for mRNA Science
Moderna and IBM to Explore Quantum Computing and Generative AI for mRNA Science
BioSpace
Moderna Therapeutics
IBM
artificial intelligence
quantum computing
Flag link:
Where Will Moderna Be in 1 Year?
Where Will Moderna Be in 1 Year?
Motley Fool
Moderna Therapeutics
MRNA
vaccines
COVID-19
RSV
CMV
Flag link:
‘Welcome to the mRNAge’: Moderna launches global mRNA campaign
‘Welcome to the mRNAge’: Moderna launches global mRNA campaign
Medical Marketing and Media
Moderna Therapeutics
MRNA
vaccines
Flag link:
Moderna & Merck plan Phase 3 trial for cancer vaccine with Keytruda
Moderna & Merck plan Phase 3 trial for cancer vaccine with Keytruda
Biopharma Reporter
Merck
Moderna Therapeutics
cancer
cancer vaccines
Keytruda
clinical trials
Flag link:
Can Pfizer Beat GSK and Moderna in This $10 Billion Market?
Can Pfizer Beat GSK and Moderna in This $10 Billion Market?
Motley Fool
Pfizer
GSK
Moderna Therapeutics
Flag link:
Moderna announces new vaccine candidates against Lyme disease and norovirus
Moderna announces new vaccine candidates against Lyme disease and norovirus
Biopharma Reporter
Moderna Therapeutics
MRNA
vaccines
Lyme disease
norovirus
Flag link:

Pages